Brokerages Set Delcath Systems, Inc. (NASDAQ:DCTH) Target Price at $22.50

Delcath Systems, Inc. (NASDAQ:DCTH) has been assigned a consensus recommendation of “Moderate Buy” from the six research firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $22.50.

Several equities analysts have recently issued reports on DCTH shares. Wall Street Zen cut Delcath Systems from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Evercore set a $27.00 target price on Delcath Systems in a research note on Thursday, February 26th. Weiss Ratings restated a “sell (d+)” rating on shares of Delcath Systems in a research note on Monday, December 29th. HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of Delcath Systems in a research note on Friday, January 9th. Finally, BTIG Research decreased their target price on Delcath Systems from $23.00 to $19.00 and set a “buy” rating for the company in a research note on Thursday, February 26th.

Delcath Systems Stock Performance

Shares of DCTH opened at $10.64 on Tuesday. The stock has a 50-day simple moving average of $9.66 and a 200-day simple moving average of $9.86. The stock has a market capitalization of $366.65 million, a PE ratio of 152.00 and a beta of 0.44. Delcath Systems has a 1 year low of $8.12 and a 1 year high of $18.23.

Delcath Systems (NASDAQ:DCTH) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.01. The business had revenue of $20.73 million during the quarter, compared to analysts’ expectations of $20.35 million. Delcath Systems had a return on equity of 2.63% and a net margin of 3.17%. Analysts predict that Delcath Systems will post -0.86 EPS for the current year.

Institutional Investors Weigh In On Delcath Systems

Institutional investors have recently added to or reduced their stakes in the business. Deutsche Bank AG increased its position in Delcath Systems by 5.4% during the fourth quarter. Deutsche Bank AG now owns 24,162 shares of the company’s stock worth $244,000 after buying an additional 1,248 shares during the period. California State Teachers Retirement System acquired a new position in Delcath Systems during the second quarter worth approximately $26,000. Intech Investment Management LLC increased its position in Delcath Systems by 13.1% during the fourth quarter. Intech Investment Management LLC now owns 17,595 shares of the company’s stock worth $178,000 after buying an additional 2,035 shares during the period. AWM Investment Company Inc. increased its position in Delcath Systems by 3.9% during the fourth quarter. AWM Investment Company Inc. now owns 60,000 shares of the company’s stock worth $606,000 after buying an additional 2,279 shares during the period. Finally, Russell Investments Group Ltd. acquired a new position in Delcath Systems during the third quarter worth approximately $29,000. Hedge funds and other institutional investors own 61.12% of the company’s stock.

About Delcath Systems

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.